The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.
OBJECTIVE
To determine if vitamin D is more effective than no therapy or calcium alone in the management of corticosteroid-induced osteoporosis, and to determine how vitamin D compares with other osteoporosis therapies, e.g., bisphosphonates, calcitonin, or fluoride, for this condition.


METHODS
We evaluated all formulations of vitamin D, including its active metabolites and analogs. A systematic search for published and unpublished studies was conducted using MEDLINE (1966-December 1997), bibliographic references, abstracts from proceedings of recent national meetings, and contact with pharmaceutical companies and content experts. We included all randomized controlled trials lasting at least 6 months (and reporting extractable results), of patients receiving oral corticosteroids, that compared vitamin D with either 1) no therapy or calcium alone, or 2) bisphosphonates, calcitonin, or fluoride. The primary outcome measure of interest was change in lumbar spine bone mineral density.


RESULTS
We found a moderate beneficial effect of vitamin D plus calcium versus no therapy or calcium alone (9 trials) (effect size 0.60; 95% confidence interval [95% CI] 0.34, 0.85; P < 0.0001). In comparisons of vitamin D with other osteoporosis therapies, bisphosphonates were more effective than vitamin D (6 trials) (effect size 0.57; 95% CI 0.09, 1.05). Calcitonin was similar in efficacy to vitamin D (4 trials) (effect size 0.03; 95% CI -0.39, 0.45). Fluoride was more effective than vitamin D, but there were only 2 trials.


CONCLUSIONS
Vitamin D plus calcium is superior to no therapy or calcium alone in the management of corticosteroid-induced osteoporosis. Vitamin D is less effective than some osteoporosis therapies. Therefore, treatment with vitamin D plus calcium, as a minimum, should be recommended to patients receiving long-term corticosteroids.
Amin
S
S
Boston University Arthritis Center, Massachusetts 02118, USA.
LaValley
M P
MP
Simms
R W
RW
Felson
D T
DT
D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D010024:Osteoporosis / Q000139:chemically induced* / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D014807:Vitamin D / Q000502:physiology*
D000305:Adrenal Cortex Hormones; D014807:Vitamin D